Compare Mesoblast Limited (MESO) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs VNET Group Inc — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while VNET Group Inc trades at $7.78 (market cap $2.19B). The key difference: Mesoblast Limited and VNET Group Inc are close in size by market cap, and Mesoblast Limited is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals.
| MESO | VNET | |
|---|---|---|
Market Cap | $2.17B | $2.19B |
Sector | Technology | Technology |
52-Week High | $20.96 | $14.03 |
52-Week Low | $12.88 | $7.34 |
Enterprise Value | $2.17B | $5.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
VNET Group trades at $7.675, up 3.86% today, but technical indicators signal a bearish trend with moving averages unanimously negative. The company reported a net loss of $256.77 million in 2025, with negative profit margins and ROE, though revenue grew to $9.95 billion. Recent news highlights strategic investments in AI and data center capacity, alongside a class action settlement announcement.
The outlook is mixed: analyst consensus is 62.5% buy with a 54% upside target, but persistent losses and bearish technicals pose risks. Investment opportunity hinges on execution of growth initiatives in AI-driven demand, while key risks include profitability challenges and competitive pressures in the data center market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
